NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Standard

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. / Stupp, Roger; Wong, Eric T; Kanner, Andrew A; Steinberg, David; Engelhard, Herbert; Heidecke, Volkmar; Kirson, Eilon D; Taillibert, Sophie; Liebermann, Frank; Dbalý, Vladimir; Ram, Zvi; Villano, J Lee; Rainov, Nikolai; Weinberg, Uri; Schiff, David; Kunschner, Lara; Raizer, Jeffrey; Honnorat, Jerome; Sloan, Andrew; Malkin, Mark; Landolfi, Joseph C; Payer, Franz; Mehdorn, Maximilian; Weil, Robert J; Pannullo, Susan C; Westphal, Manfred; Smrcka, Martin; Chin, Lawrence; Kostron, Herwig; Hofer, Silvia; Bruce, Jeffrey; Cosgrove, Rees; Paleologous, Nina; Palti, Yoram; Gutin, Philip H.

In: EUR J CANCER, Vol. 48, No. 14, 14, 2012, p. 2192-2202.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stupp, R, Wong, ET, Kanner, AA, Steinberg, D, Engelhard, H, Heidecke, V, Kirson, ED, Taillibert, S, Liebermann, F, Dbalý, V, Ram, Z, Villano, JL, Rainov, N, Weinberg, U, Schiff, D, Kunschner, L, Raizer, J, Honnorat, J, Sloan, A, Malkin, M, Landolfi, JC, Payer, F, Mehdorn, M, Weil, RJ, Pannullo, SC, Westphal, M, Smrcka, M, Chin, L, Kostron, H, Hofer, S, Bruce, J, Cosgrove, R, Paleologous, N, Palti, Y & Gutin, PH 2012, 'NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.', EUR J CANCER, vol. 48, no. 14, 14, pp. 2192-2202. <http://www.ncbi.nlm.nih.gov/pubmed/22608262?dopt=Citation>

APA

Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., Ram, Z., Villano, J. L., Rainov, N., Weinberg, U., Schiff, D., Kunschner, L., Raizer, J., Honnorat, J., Sloan, A., ... Gutin, P. H. (2012). NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. EUR J CANCER, 48(14), 2192-2202. [14]. http://www.ncbi.nlm.nih.gov/pubmed/22608262?dopt=Citation

Vancouver

Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. EUR J CANCER. 2012;48(14):2192-2202. 14.

Bibtex

@article{3de7c08d1fd44d6a98c3fe6fc13b8f94,

title = "NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.",

abstract = "NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division.",

keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Risk Factors, Quality of Life, Young Adult, Treatment Outcome, Europe, Risk Assessment, Time Factors, Disease-Free Survival, Proportional Hazards Models, United States, Karnofsky Performance Status, Magnetic Resonance Imaging, Kaplan-Meier Estimate, *Neoplasm Recurrence, Local, Israel, Antineoplastic Agents/adverse effects/*therapeutic use, Brain Neoplasms/drug therapy/mortality/pathology/*therapy, *Electric Stimulation Therapy/adverse effects, Glioblastoma/drug therapy/mortality/pathology/*therapy, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Risk Factors, Quality of Life, Young Adult, Treatment Outcome, Europe, Risk Assessment, Time Factors, Disease-Free Survival, Proportional Hazards Models, United States, Karnofsky Performance Status, Magnetic Resonance Imaging, Kaplan-Meier Estimate, *Neoplasm Recurrence, Local, Israel, Antineoplastic Agents/adverse effects/*therapeutic use, Brain Neoplasms/drug therapy/mortality/pathology/*therapy, *Electric Stimulation Therapy/adverse effects, Glioblastoma/drug therapy/mortality/pathology/*therapy",

author = "Roger Stupp and Wong, {Eric T} and Kanner, {Andrew A} and David Steinberg and Herbert Engelhard and Volkmar Heidecke and Kirson, {Eilon D} and Sophie Taillibert and Frank Liebermann and Vladimir Dbal{\'y} and Zvi Ram and Villano, {J Lee} and Nikolai Rainov and Uri Weinberg and David Schiff and Lara Kunschner and Jeffrey Raizer and Jerome Honnorat and Andrew Sloan and Mark Malkin and Landolfi, {Joseph C} and Franz Payer and Maximilian Mehdorn and Weil, {Robert J} and Pannullo, {Susan C} and Manfred Westphal and Martin Smrcka and Lawrence Chin and Herwig Kostron and Silvia Hofer and Jeffrey Bruce and Rees Cosgrove and Nina Paleologous and Yoram Palti and Gutin, {Philip H}",

year = "2012",

language = "English",

volume = "48",

pages = "2192--2202",

journal = "EUR J CANCER",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "14",

}

RIS

TY - JOUR

T1 - NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

AU - Stupp, Roger

AU - Wong, Eric T

AU - Kanner, Andrew A

AU - Steinberg, David

AU - Engelhard, Herbert

AU - Heidecke, Volkmar

AU - Kirson, Eilon D

AU - Taillibert, Sophie

AU - Liebermann, Frank

AU - Dbalý, Vladimir

AU - Ram, Zvi

AU - Villano, J Lee

AU - Rainov, Nikolai

AU - Weinberg, Uri

AU - Schiff, David

AU - Kunschner, Lara

AU - Raizer, Jeffrey

AU - Honnorat, Jerome

AU - Sloan, Andrew

AU - Malkin, Mark

AU - Landolfi, Joseph C

AU - Payer, Franz

AU - Mehdorn, Maximilian

AU - Weil, Robert J

AU - Pannullo, Susan C

AU - Westphal, Manfred

AU - Smrcka, Martin

AU - Chin, Lawrence

AU - Kostron, Herwig

AU - Hofer, Silvia

AU - Bruce, Jeffrey

AU - Cosgrove, Rees

AU - Paleologous, Nina

AU - Palti, Yoram

AU - Gutin, Philip H

PY - 2012

Y1 - 2012

N2 - NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division.

AB - NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Risk Factors

KW - Quality of Life

KW - Young Adult

KW - Treatment Outcome

KW - Europe

KW - Risk Assessment

KW - Time Factors

KW - Disease-Free Survival

KW - Proportional Hazards Models

KW - United States

KW - Karnofsky Performance Status

KW - Magnetic Resonance Imaging

KW - Kaplan-Meier Estimate

KW - Neoplasm Recurrence, Local

KW - Israel

KW - Antineoplastic Agents/adverse effects/therapeutic use

KW - Brain Neoplasms/drug therapy/mortality/pathology/therapy

KW - Electric Stimulation Therapy/adverse effects

KW - Glioblastoma/drug therapy/mortality/pathology/therapy